A phase 2 study showed that the novel selective aldosterone synthase inhibitor BI 690517 improved albuminuria reduction in patients with chronic kidney disease. When combined with empagliflozin, it provided kidney protection without increasing hyperkalemia risk. The study included 714 participants who had been on an ACE inhibitor or angiotensin receptor blocker for at least 4 weeks. BI 690517 reduced albuminuria, lowered systolic blood pressure, and there were no unexpected safety issues. Experts caution that long-term benefits and hard outcomes such as end-stage kidney disease and death need to be assessed in a phase 3 study. A phase 3 clinical trial with 11,000 participants is planned.
Source link
Novel Aldosterone Synthase Inhibitor Could Enhance CKD Therapy
